Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Imclone systems (IMCL) -- Ignore unavailable to you. Want to Upgrade?

To: Jim who wrote (1036)	10/7/1999 7:59:00 AM
From: xcr600	Read Replies (1) \| Respond to of 2515

Here ya go........ biz.yahoo.com Thursday October 7, 6:03 am Eastern Time Company Press Release ImClone Investor Call for 9:00 AM EDT October 7, 1999 NEW YORK--(BW HealthWire)--Oct. 7, 1999--ImClone Systems Incorporated's (Nasdaq: IMCL - news) lead product candidate, C225, is an antibody antagonist to the Epidermal Growth Factor receptor that is currently in Phase III clinical trials for the treatment, in conjunction with radiation therapy or chemotherapy, of EGF receptor positive tumors. ImClone has become aware of a U.S. patent issued to a third party that includes claims relating to the potential use, subject to certain restrictions, of EGF receptor antibodies in conjunction with cytotoxic factors to inhibit tumor growth. Outside patent counsel to the Company has reviewed the patent and has indicated that in such counsel's opinion, ImClone will be able to commercialize C225 upon FDA approval without infringing this third party patent. To explain and clarify this issue ImClone will be conducting an investor conference call at 9:00 AM EDT at 1-800-510-0141 password 1405. ImClone Systems Incorporated, headquartered in New York, is a biopharmaceutical company developing novel cancer therapeutic products including interventional therapeutics, cancer vaccines and blood cell growth factors for the treatment of cancer and cancer-related disorders. Contact: ImClone Systems Incorporated Andrea F. Rabney, 212/645-1405 Senior Director of Corporate Development Investor Relations or Burns McClellan, Inc. Jonathan M. Nugent (investors) or Justin Jackson (media) 212/213-0006